Hand Function after Distal Radial Access: Is it Safe?

The benefit of the transradial approach in percutaneous interventions is well known. Its main limitation is radial artery occlusion (RAO) which would compromise the artery for future use in percutaneous procedures. Even though it is clinically silent, reported cases might reach 33%. 

Función de la mano luego del acceso radial distal, ¿es seguro?

More recently, the distal radial access (DRA) has surged as an alternative to reduce RAO. However, its safety and potential to produce negative effects in hand function have not been studied yet. 

The aim of this prospective, multicenter, cohort study was to assess hand function at long term in patients treated with DRA for coronary procedures. 

Multiple outcomes were presented to assess hand dysfunction, including coordination questionnaires, dexterity, strength, and sensation tests up to 12-month followup. 

The study looked at 313 patients. Mean age was 66 and they were mostly men. 22% presented prior radial access. As regards procedure characteristics, 54% of DRA was left, ultrasound was used to guide puncture in 85 % of cases, and they were mostly diagnostic procedures. DRA failed in 2.9% of cases. 

Read also: FFR and IFR: Are We Talking About the Same Thing?

DRA showed no hand function deterioration according to the questionnaires for subjective and objective assessment and was even associated to less pain and <1% RAO rate.  

Conclusion 

The distal radial access was not associated with worse hand function. On the contrary, it was associated to lower complications rate with good tolerance to the procedure. 

Dr. Andrés Rodríguez
Member of the editorial board of SOLACI.org.

Original Title: International Hand Function Study Following Distal Radial Access The RATATOUILLE Study.

Reference: Gregory A. Sgueglia, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...